960 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Avestar Capital LLC

Avestar Capital LLC acquired a new stake in Insulet Co. (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 960 shares of the medical instruments supplier’s stock, valued at approximately $223,000.

A number of other institutional investors also recently modified their holdings of the stock. QRG Capital Management Inc. bought a new stake in shares of Insulet during the third quarter valued at approximately $297,000. Diversified Trust Co boosted its stake in Insulet by 90.9% in the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after acquiring an additional 4,348 shares during the last quarter. Linden Thomas Advisory Services LLC boosted its stake in Insulet by 65.8% in the second quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier’s stock valued at $1,778,000 after acquiring an additional 3,497 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Insulet by 38.8% in the second quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock valued at $36,202,000 after acquiring an additional 50,101 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in Insulet by 23.9% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 35,035 shares of the medical instruments supplier’s stock valued at $6,006,000 after acquiring an additional 6,754 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent research reports. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Citigroup raised their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Morgan Stanley increased their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Barclays increased their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Canaccord Genuity Group increased their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Trading Up 0.2 %

Shares of NASDAQ:PODD opened at $266.92 on Friday. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company’s fifty day simple moving average is $243.21 and its 200 day simple moving average is $212.74. The firm has a market cap of $18.72 billion, a price-to-earnings ratio of 45.71, a PEG ratio of 4.08 and a beta of 1.22.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.